La maladie de Parkinson en France (serveur d'exploration)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Effect of bilateral subthalamic nucleus stimulation and dopatherapy on oral control in Parkinson's disease.

Identifieur interne : 004359 ( Main/Merge ); précédent : 004358; suivant : 004360

Effect of bilateral subthalamic nucleus stimulation and dopatherapy on oral control in Parkinson's disease.

Auteurs : M. Gentil [France] ; C L Tournier ; P. Pollak ; A L Benabid

Source :

RBID : pubmed:10529538

English descriptors

Abstract

This study focuses on the speech organs of a parkinsonian patient who initially had been treated with levodopa for 13 years, and had become severely disabled by motor fluctuations. This patient has been treated with bilateral chronic stimulation of the subthalamic nucleus (STN) for the last 2 years. Upper lip, lower lip and tongue force production were examined before surgery under off and on medication conditions, and 2 years after surgery under off and on stimulation conditions. We compared the effect of stimulation and dopatherapy on the speech organs. L-Dopa had a poor effect whereas bilateral stimulation improved oral control and speech intelligibility. These results suggest that STN stimulation influences speech organs in a different way from the dopaminergic system and similarly affects oral and limb motor systems.

DOI: 8087
PubMed: 10529538

Links toward previous steps (curation, corpus...)


Links to Exploration step

pubmed:10529538

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Effect of bilateral subthalamic nucleus stimulation and dopatherapy on oral control in Parkinson's disease.</title>
<author>
<name sortKey="Gentil, M" sort="Gentil, M" uniqKey="Gentil M" first="M" last="Gentil">M. Gentil</name>
<affiliation wicri:level="3">
<nlm:affiliation>INSERM, U 318, Centre Hospitalier Universitaire, Grenoble, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>INSERM, U 318, Centre Hospitalier Universitaire, Grenoble</wicri:regionArea>
<placeName>
<region type="region">Auvergne-Rhône-Alpes</region>
<region type="old region">Rhône-Alpes</region>
<settlement type="city">Grenoble</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Tournier, C L" sort="Tournier, C L" uniqKey="Tournier C" first="C L" last="Tournier">C L Tournier</name>
</author>
<author>
<name sortKey="Pollak, P" sort="Pollak, P" uniqKey="Pollak P" first="P" last="Pollak">P. Pollak</name>
</author>
<author>
<name sortKey="Benabid, A L" sort="Benabid, A L" uniqKey="Benabid A" first="A L" last="Benabid">A L Benabid</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="1999">1999</date>
<idno type="RBID">pubmed:10529538</idno>
<idno type="pmid">10529538</idno>
<idno type="doi">8087</idno>
<idno type="wicri:Area/PubMed/Corpus">001432</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001432</idno>
<idno type="wicri:Area/PubMed/Curation">001391</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001391</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001391</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001391</idno>
<idno type="wicri:Area/Ncbi/Merge">000073</idno>
<idno type="wicri:Area/Ncbi/Curation">000073</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000073</idno>
<idno type="wicri:doubleKey">0014-3022:1999:Gentil M:effect:of:bilateral</idno>
<idno type="wicri:Area/Main/Merge">004359</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Effect of bilateral subthalamic nucleus stimulation and dopatherapy on oral control in Parkinson's disease.</title>
<author>
<name sortKey="Gentil, M" sort="Gentil, M" uniqKey="Gentil M" first="M" last="Gentil">M. Gentil</name>
<affiliation wicri:level="3">
<nlm:affiliation>INSERM, U 318, Centre Hospitalier Universitaire, Grenoble, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>INSERM, U 318, Centre Hospitalier Universitaire, Grenoble</wicri:regionArea>
<placeName>
<region type="region">Auvergne-Rhône-Alpes</region>
<region type="old region">Rhône-Alpes</region>
<settlement type="city">Grenoble</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Tournier, C L" sort="Tournier, C L" uniqKey="Tournier C" first="C L" last="Tournier">C L Tournier</name>
</author>
<author>
<name sortKey="Pollak, P" sort="Pollak, P" uniqKey="Pollak P" first="P" last="Pollak">P. Pollak</name>
</author>
<author>
<name sortKey="Benabid, A L" sort="Benabid, A L" uniqKey="Benabid A" first="A L" last="Benabid">A L Benabid</name>
</author>
</analytic>
<series>
<title level="j">European neurology</title>
<idno type="ISSN">0014-3022</idno>
<imprint>
<date when="1999" type="published">1999</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Analysis of Variance</term>
<term>Antiparkinson Agents (administration & dosage)</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Articulation Disorders (drug therapy)</term>
<term>Articulation Disorders (etiology)</term>
<term>Articulation Disorders (physiopathology)</term>
<term>Articulation Disorders (therapy)</term>
<term>Dopamine Agents (administration & dosage)</term>
<term>Dopamine Agents (therapeutic use)</term>
<term>Electric Stimulation Therapy</term>
<term>Electrodes, Implanted</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Levodopa (administration & dosage)</term>
<term>Levodopa (therapeutic use)</term>
<term>Lip (physiopathology)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Parkinson Disease (complications)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (physiopathology)</term>
<term>Parkinson Disease (therapy)</term>
<term>Pulse Therapy, Drug</term>
<term>Reaction Time</term>
<term>Subthalamic Nucleus (surgery)</term>
<term>Tongue (physiopathology)</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en">
<term>Antiparkinson Agents</term>
<term>Dopamine Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en">
<term>Antiparkinson Agents</term>
<term>Dopamine Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en">
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en">
<term>Articulation Disorders</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en">
<term>Articulation Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en">
<term>Articulation Disorders</term>
<term>Lip</term>
<term>Parkinson Disease</term>
<term>Tongue</term>
</keywords>
<keywords scheme="MESH" qualifier="surgery" xml:lang="en">
<term>Subthalamic Nucleus</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en">
<term>Articulation Disorders</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Analysis of Variance</term>
<term>Electric Stimulation Therapy</term>
<term>Electrodes, Implanted</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Pulse Therapy, Drug</term>
<term>Reaction Time</term>
<term>Treatment Outcome</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">This study focuses on the speech organs of a parkinsonian patient who initially had been treated with levodopa for 13 years, and had become severely disabled by motor fluctuations. This patient has been treated with bilateral chronic stimulation of the subthalamic nucleus (STN) for the last 2 years. Upper lip, lower lip and tongue force production were examined before surgery under off and on medication conditions, and 2 years after surgery under off and on stimulation conditions. We compared the effect of stimulation and dopatherapy on the speech organs. L-Dopa had a poor effect whereas bilateral stimulation improved oral control and speech intelligibility. These results suggest that STN stimulation influences speech organs in a different way from the dopaminergic system and similarly affects oral and limb motor systems.</div>
</front>
</TEI>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004359 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 004359 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonFranceV1
   |flux=    Main
   |étape=   Merge
   |type=    RBID
   |clé=     pubmed:10529538
   |texte=   Effect of bilateral subthalamic nucleus stimulation and dopatherapy on oral control in Parkinson's disease.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Merge/RBID.i   -Sk "pubmed:10529538" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Merge/biblio.hfd   \
       | NlmPubMed2Wicri -a ParkinsonFranceV1 

Wicri

This area was generated with Dilib version V0.6.29.
Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024